JPMorgan Chase & Co. Lowers Hikma Pharmaceuticals (OTCMKTS:HKMPF) to Neutral

JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals (OTCMKTS:HKMPFGet Rating) from an overweight rating to a neutral rating in a research report report published on Wednesday morning, The Fly reports.

A number of other brokerages have also weighed in on HKMPF. Morgan Stanley decreased their target price on Hikma Pharmaceuticals from GBX 2,300 ($28.94) to GBX 2,100 ($26.43) in a research note on Friday, May 6th. Zacks Investment Research cut Hikma Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, May 4th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Hikma Pharmaceuticals currently has an average rating of Buy and an average price target of $1,677.00.

Shares of OTCMKTS HKMPF opened at $20.82 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.38 and a current ratio of 2.06. The stock’s 50-day simple moving average is $25.34 and its two-hundred day simple moving average is $27.16. Hikma Pharmaceuticals has a twelve month low of $20.82 and a twelve month high of $37.70.

About Hikma Pharmaceuticals (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Further Reading

The Fly logo

Analyst Recommendations for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with's FREE daily email newsletter.